| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 28, 2024 |
| Accession Number: | 0001193125-24-075257 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2024 | Outperform → Mkt Perform | Raymond James | |
| 8/14/2023 | $18.00 | Buy | UBS |
| 8/11/2023 | $20.00 | Buy | Guggenheim |
| 4/5/2023 | Outperform | William Blair | |
| 3/9/2023 | $15.00 | Buy | BTIG Research |
| 4/11/2022 | $9.00 | Overweight | Cantor Fitzgerald |
| 11/11/2021 | $12.00 → $14.00 | Strong Buy | Raymond James |
| 8/3/2021 | $13.00 → $12.00 | Buy | HC Wainwright & Co. |
Acquisition Reinforces Gilead's Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (NASDAQ:GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (NASDAQ:CBAY) for approximately $4.3 billion in total equity value. The addition of CymaBay's investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead's existing liver portfolio and aligns with its long-standing commitment to bringing transformational medicines to patients. "The acquisition of CymaBay brings us a potential best in disease therapy that
NEWARK, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the Marketing Authorization Application (MAA) for seladelpar, for the treatment of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid), has been validated and will now be reviewed by the European Medicines Agency (EMA). Seladelpar is an investigational, potent, selective peroxisome proliferator-activated receptor delta (PPARδ)
Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. U.S. FDA accepted seladelpar NDA for priority review, and seladelpar marketing applications were submitted to the EMA and MHRA for review in Europe and the U.K. Due to the pending transaction with Gilead, CymaBay will not be hosting a conference call to review the financial results for the fourth quarter ended December 31, 2023 or commenting on its financial guidance for the future quarters. NEWARK, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing thera
Raymond James downgraded CymaBay Therapeutics from Outperform to Mkt Perform
UBS initiated coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $18.00
Guggenheim initiated coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $20.00
4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)
4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)
4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)
15-12G - CymaBay Therapeutics, Inc. (0001042074) (Filer)
EFFECT - CymaBay Therapeutics, Inc. (0001042074) (Filer)
EFFECT - CymaBay Therapeutics, Inc. (0001042074) (Filer)
Submission status for CYMABAY THERAPEUTICS INC's drug LIVDELZI (ORIG-1) with active ingredient SELADELPAR has changed to 'Approval' on 08/14/2024. Application Category: NDA, Application Number: 217899, Application Classification: Type 1 - New Molecular Entity
NEWARK, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Charles McWherter as President of Research and Development. "We are excited to announce the promotion of Chuck to President of Research and Development, in addition to his continuing role as Chief Scientific Officer. Chuck joined CymaBay in 2007 and has served as Chief Scientific Officer since 2013. In this role he has been instrumental in the development of seladelpar. Chuck's extensive experience in the pharmaceutical industry
NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Éric Lefebvre to its Board of Directors. "We are excited to be welcoming Éric to the Board. Éric's extensive experience in the pharmaceutical industry as an executive focused on clinical development, medical affairs, business development and life-cycle strategy and more than 10 years of experience developing drugs in liver disease indications make him a perfect addition to our Board. We look forward to Éric helping guide us thr
NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of biopharma veteran Thomas Wiggans and commercial leader Janet Dorling to its Board of Directors. Concurrently with these appointments, CymaBay announced that Paul F. Truex has resigned from the Board of Directors effective as of April 1, 2021 to focus on his new role as Chief Executive Officer of LQT Therapeutics. “We are truly excited to be welcoming Tom and Janet to the Board. Tom’s experience leading biopharma companies, such a
Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. U.S. FDA accepted seladelpar NDA for priority review, and seladelpar marketing applications were submitted to the EMA and MHRA for review in Europe and the U.K. Due to the pending transaction with Gilead, CymaBay will not be hosting a conference call to review the financial results for the fourth quarter ended December 31, 2023 or commenting on its financial guidance for the future quarters. NEWARK, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing thera
NEWARK, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that it will host a conference call and live audio webcast on Tuesday, November 7, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2023 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 1-877-407-0784 from the U.S. and Canada, or 1-201-689-8560 internationally, Conference ID #13740701. To access the live and subsequently archived webcast of the conference call, go t
Primary composite endpoint at 12 months of serum alkaline phosphatase and bilirubin was met by 61.7% of patients treated with seladelpar 10 mg vs. 20.0% of placebo treated patients (p<0.0001) Normalization of alkaline phosphatase at 12 months was achieved by 25.0% of patients treated with seladelpar vs. 0% on placebo (p<0.0001) In patients having moderate-to-severe itch at baseline, the seladelpar treated group improved their pruritus at 6 months compared to those in the placebo group (p<0.005) Safety and tolerability were comparable between placebo and seladelpar groups and consistent with previous studies CymaBay will hold a conference call to discuss these results today at 8:00 a.m. ET N
SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)
SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)
SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)